Skip to Content

IP 253 (Ranitidine 150 mg)

Pill imprint IP 253 has been identified as Ranitidine hydrochloride 150 mg.

Ranitidine is used in the treatment of gerd; gastric ulcer maintenance treatment; erosive esophagitis; duodenal ulcer; eczema (and more), and belongs to the drug class H2 antagonists. There is no proven risk in humans during pregnancy. Ranitidine 150 mg is not subject to the Controlled Substances Act.

See also related documents.

Ranitidine hydrochloride 150 mg IP 253
Ranitidine hydrochloride 150 mg IP 253
Ranitidine hydrochloride 150 mg IP 253  Front
Ranitidine hydrochloride 150 mg IP 253  Back
Ranitidine hydrochloride 150 mg IP 253
Ranitidine hydrochloride
IP 253
150 mg
9.00 mm
Rx and/or OTC
Drug Class:
H2 antagonists
Pregnancy Category:
B - No proven risk in humans
CSA Schedule:
N - Not a controlled drug
Amneal Pharmaceuticals
National Drug Code (NDC):
Other Manufacturers / Repackagers:
NDC CodeManufacturer / Repackager
65162-0253 Amneal Pharmaceuticals LLC
00904-6080 Major Pharmaceuticals
66267-0188 Nucare Pharmaceuticals Inc (repackager)
68071-1321 Nucare Pharmaceuticals Inc (repackager)

Note: Inactive ingredients may vary.

View Details Print Page

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2015, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.